MV-NIS

also known as oncolytic measles virus encoding thyroidal sodium iodide symporter · Modified Measles Virus

Developed for: fallopian tube clear cell adenocarcinoma · fallopian tube endometrioid adenocarcinoma · fallopian tube mucinous adenocarcinoma · fallopian tube serous adenocarcinoma · fallopian tube transitional cell carcinoma · ovarian clear cell adenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian mucinous adenocarcinoma
+23 more
· ovarian seromucinous carcinoma · ovarian serous adenocarcinoma · ovarian transitional cell carcinoma · plasma cell myeloma · primary peritoneal serous adenocarcinoma · undifferentiated ovarian carcinoma · atypical teratoid rhabdoid tumor · childhood medulloblastoma · estrogen-receptor positive breast cancer · fallopian tube carcinosarcoma · head and neck squamous cell carcinoma · HER2 positive breast carcinoma · invasive breast carcinoma · malignant mesothelioma · malignant ovarian Brenner tumor · malignant peripheral nerve sheath tumor · non-small cell lung carcinoma · ovarian carcinoma · ovarian carcinosarcoma · peritoneal carcinoma · progesterone-receptor positive breast cancer · triple-negative breast carcinoma · urothelial carcinoma
Investigated by: Mayo Clinic · National Cancer Institute (NCI) · Vyriad, Inc. · No More Kids With Cancer · Sabine Mueller, MD, PhD · The Matthew Larson Foundation for Pediatric Brain Tumors
+1 more
· University of Arkansas

Trials 11 · a red edge is where a trial was stopped

today NCT03171493 · Ph 1 NCT02919449 · Ph 1 NCT02700230 · Ph 1 NCT02962167 · Ph 1 NCT02192775 · Ph 2 NCT02364713 · Ph 2 NCT02068794 · Ph 1/2 NCT01846091 · Ph 1 NCT01503177 · Ph 1 NCT00450814 · Ph 1/2 NCT00408590 · Ph 1

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 17 trials
Phase 1	NCT03171493	Jul 2018 → Feb 2021	urothelial carcinoma	Vyriad, Inc.	Completed	No outcome recorded
Phase 1	NCT02919449	Aug 2017 → Jan 2018	non-small cell lung carcinoma	Vyriad, Inc.	Terminated	No outcome recorded
Phase 1	NCT02700230	Mar 2017 → Apr 2024	malignant peripheral nerve sheath tumor, neurofibromatosis type 1	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT02962167	Feb 2017 → May 2023	atypical teratoid rhabdoid tumor, childhood medulloblastoma	Sabine Mueller, MD, PhD	Completed	No outcome recorded
Phase 1	NCT01846091	Apr 2013 → Sep 2019	HER2 positive breast carcinoma, estrogen-receptor positive breast cancer, head and neck squamous cell carcinoma, invasive breast carcinoma +2	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT01503177	Nov 2011 → Apr 2019	malignant mesothelioma	Mayo Clinic	Completed	No outcome recorded
Phase 1	NCT00408590	Apr 2004 → Aug 2012	ovarian carcinoma, peritoneal carcinoma	Mayo Clinic	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02068794	Apr 2014 → Mar 2024 overdue	fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma +10	Mayo Clinic	Active not recruiting	No outcome recorded
Phase 1/2	NCT00450814	Nov 2006 → Jul 2018	plasma cell myeloma	Mayo Clinic	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT02364713	Mar 2015 → Jan 2022	fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma +11	Mayo Clinic	Terminated	No outcome recorded
Phase 2	NCT02192775	Mar 2015 → Aug 2019	plasma cell myeloma	University of Arkansas	Completed	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

Field	Value	Cited text
Known as	MV-NIS	“To determine the maximally tolerated dose (MTD) of intratumoral administration of an Edmonston strain measles virus genetically engineered to express human thyroidal...” NCT01846091 ↗ 8 “Determine the safety and toxicity of recombinant carcinoembryonic antigen (CEA)-expressing measles virus (MV-CEA) and oncolytic measles virus encoding thyroidal sodium iodide...” NCT00408590 ↗ “Patients receive the oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) intrapleurally.” NCT01503177 ↗ “oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS)” NCT02068794 ↗ “oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS)” NCT02364713 ↗ “Patients receive MV-NIS intratumorally on day 1.” NCT02700230 ↗ NCT03171493 ↗ NCT02192775 ↗ NCT02919449 ↗
Known as	Modified Measles Virus	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02962167 ↗
Known as	oncolytic measles virus encoding thyroidal sodium iodide symporter	“Patients receive the oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) intrapleurally.” NCT01503177 ↗ 1 NCT00450814 ↗
Modality	Other / unclassified	“modified measles virus (MV-NIS)” NCT02962167 ↗
Route	Other	“Patients receive recombinant carcinoembryonic antigen-expressing measles virus (MV-CEA) or oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS)...” NCT00408590 ↗